Clinical Trials Logo

Relapsed T-Cell Lymphoma clinical trials

View clinical trials related to Relapsed T-Cell Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04251065 Active, not recruiting - Clinical trials for Relapsed T-Cell Lymphoma

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Start date: September 3, 2020
Phase: Phase 2
Study type: Interventional

FIL_Dara-GDP is a phase II, open label, multicenter clinical trial. The sponsor of this clinical trial is Fondazione Italiana Linfomi (FIL). The primary objective is to evaluate the efficacy of 4 courses of D-GDP (Daratumumab in combination with Gemcitabine, Cisplatin, Dexamethasone) in terms of complete response in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of T follicular helper cells (TFH cells) origin refractory/relapsed after at least one and no more than two previous lines of therapy.

NCT ID: NCT04191187 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

Start date: December 6, 2019
Phase: Phase 2
Study type: Interventional

This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation). Peripheral blood is the donor graft source. This study is designed to estimate disease-free survival (DFS) at 18 months post-transplant.

NCT ID: NCT03674411 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Start date: January 2, 2019
Phase: Phase 2
Study type: Interventional

This is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L, IL-6 and thromopoietin) on lympho-hematopoietic recovery. Patients will receive a uniform myeloablative conditioning and post-transplant immunoprophylaxis.

NCT ID: NCT02722668 Active, not recruiting - Multiple Myeloma Clinical Trials

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Start date: May 15, 2017
Phase: Phase 2
Study type: Interventional

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.